OWC Pharmaceutical Research Corp Appoints Dr. Stan
Post# of 15624
(Total Views: 189)
Posted On: 07/24/2017 4:20:44 PM
OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its active Chairman
Dr. Hirsch has extensive scientific, executive and board level experience, directly related to OWCP's current scientific and business development efforts.
https://www.otcmarkets.com/stock/OWCP/filings
https://www.otcmarkets.com/edgar/GetFilingHtm...D=12186192
PETACH TIKVA, Israel, July 25th, 2017 /PRNewswire/
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active Chairman of the board of directors .
Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.
From May 2016 to the present, Dr. Hirsch has served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd (NASDAQ: FOMX), an Israeli-based clinical-stage specialty pharmaceutical company in late-stage clinical development and commercializing two proprietary products for the treatment of acne, rosacea and other skin conditions. Foamix collaborates with leading global pharmaceutical companies in the creation and commercialization of its advanced skin treatment products.
Dr. Hirsch has served as Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc, which was listed on the AIM-London Stock Exchange, prior to acquisition by Suzano Pulp and Paper of Brazil (SUZB, BOVESPA, Sao Paulo) in July 2010 . FuturaGene Limited is a world leader in the development of environmentally friendly solutions that improve and protect crop yields, engaged in the development and delivery of sustainable genetic solutions for global forestry, biopower, biofuels, and agricultural markets.
Dr. Hirsch’s educational experience includes a D.Phil [PhD] in Cell Biology and Immunology from Oxford University, UK, in 1982, a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa in 1979, among other academic honors and awards from Oxford University and University of Capetown.
Mr. Mordechai Bignitz Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Hirsch agreeing to join OWCP and assume the role of active chairman. I have known Dr. Hirsch for many years and cooperated with him in the past. Dr. Hirsch brings with him a unique set of skills, both scientific and business, that are in the exact scope of our operations. I am sure that his contribution to our growth will be of major significance.
Dr. Stanley Hirsch commented on his new role "I feel privileged to have received the invitation to serve as OWCP’s active chairman. I have known Mr. Bignitz for more than 20 years and we cooperated extremely successfully in the past. I received an in depth scientific overview from OWCP's CSO, Dr. Yehuda Baruch and I am sure OWCP's intellectual assets and scientific achievements position it most advantageously to become a world leader in the field of Cannabis based scientific products.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
For more information visit: http://www.owcpharma.com/
Dr. Hirsch has extensive scientific, executive and board level experience, directly related to OWCP's current scientific and business development efforts.
https://www.otcmarkets.com/stock/OWCP/filings
https://www.otcmarkets.com/edgar/GetFilingHtm...D=12186192
PETACH TIKVA, Israel, July 25th, 2017 /PRNewswire/
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active Chairman of the board of directors . Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.
From May 2016 to the present, Dr. Hirsch has served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd (NASDAQ: FOMX), an Israeli-based clinical-stage specialty pharmaceutical company in late-stage clinical development and commercializing two proprietary products for the treatment of acne, rosacea and other skin conditions. Foamix collaborates with leading global pharmaceutical companies in the creation and commercialization of its advanced skin treatment products.
Dr. Hirsch has served as Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc, which was listed on the AIM-London Stock Exchange, prior to acquisition by Suzano Pulp and Paper of Brazil (SUZB, BOVESPA, Sao Paulo) in July 2010 . FuturaGene Limited is a world leader in the development of environmentally friendly solutions that improve and protect crop yields, engaged in the development and delivery of sustainable genetic solutions for global forestry, biopower, biofuels, and agricultural markets.
Dr. Hirsch’s educational experience includes a D.Phil [PhD] in Cell Biology and Immunology from Oxford University, UK, in 1982, a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa in 1979, among other academic honors and awards from Oxford University and University of Capetown.
Mr. Mordechai Bignitz Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Hirsch agreeing to join OWCP and assume the role of active chairman. I have known Dr. Hirsch for many years and cooperated with him in the past. Dr. Hirsch brings with him a unique set of skills, both scientific and business, that are in the exact scope of our operations. I am sure that his contribution to our growth will be of major significance.
Dr. Stanley Hirsch commented on his new role "I feel privileged to have received the invitation to serve as OWCP’s active chairman. I have known Mr. Bignitz for more than 20 years and we cooperated extremely successfully in the past. I received an in depth scientific overview from OWCP's CSO, Dr. Yehuda Baruch and I am sure OWCP's intellectual assets and scientific achievements position it most advantageously to become a world leader in the field of Cannabis based scientific products.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
For more information visit: http://www.owcpharma.com/
(2)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼